Affinity Peptide-Based Circularly Permuted Fluorescent Protein Biosensors for Non-Small Cell Lung Cancer Diagnosis
Sensors · 2024
DOI: 10.3390/s24247899 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sensors, 2024. Verfasst von Dengyue Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Central Hospital of Dalian University of Technology, Dalian 116021, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Biosensing Techniques, Lung Neoplasms, Keratin-19. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dalian Key R&D Program Project, Dalian Major Basic Research Projects, Dalian Key R&D Program Project.
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) is the predominant form of lung cancer and poses a significant public health challenge. Early detection is crucial for improving patient outcomes, with serum biomarkers such as carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCCAg), and cytokeratin fragment 19 (CYFRA 21-1) playing a critical role in early screening and pathological classification of NSCLC. However, due to being mainly based on corresponding antibody binding reactions, existing detection technologies for these serum biomarkers have shortcomings such as complex operations, high false positive rates, and high costs. This study aimed to develop new methods for detecting CEA, SCCAg, and CYFRA 21-1 to assist in the diagnosis of NSCLC. Affinity peptides of CEA, SCCAg, and CYFRA 21-1, respectively, were screened by phage display technology, and the peptides’ binding affinities were determined by enzyme-linked immunosorbent assay and biolayer interferometry. Peptides with high affinity were then integrated as binding domains into biosensors by fusing them with circularly permuted fluorescent proteins (cpFPs) through genetic coding. The resulting biosensors, C4 biosensor for CEA, S1 biosensor for SCCAg, and Y3 biosensor for CYFRA 21-1, demonstrated robust sensitivity and specificity even at concentrations as low as 1 ng/mL for their respective tumor markers. When applied to clinical samples and recalibrated for the upper limit of normal concentrations, the biosensors exhibited enhanced sensitivity and specificity for NSCLC diagnosis. This study introduced innovative biosensors for the detection of CEA, SCCAg, and CYFRA 21-1, providing a highly sensitive, specific, rapid, and cost-effective diagnostic alternative that could significantly improve NSCLC screening rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central Hospital of Dalian University of Technology, Dalian 116021, China.
- Liaoning Key Lab of Integrated Circuit and Biomedical Electronic System, Faculty of Medicine, Dalian University of Technology, Dalian 116024, China.
- China Certification and Inspection Group Liaoning Co., Ltd., Dalian 116039, China.
ORCID-Profile: Dengyue Xu, Hangyu Zhang, Bo Liu
Förderung
- Dalian Key R&D Program Project
- Dalian Major Basic Research Projects
- Dalian Key R&D Program Project
Zitieren
APA
Xu, D., Jiang, Q., Li, Z., Shang, A., Liu, J., Xue, C., Shao, S., Zhang, H., Yuan, H., Wu, B., & Liu, B. (2024). Affinity Peptide-Based Circularly Permuted Fluorescent Protein Biosensors for Non-Small Cell Lung Cancer Diagnosis. Sensors. https://doi.org/10.3390/s24247899
Vancouver
Xu D, Jiang Q, Li Z, Shang A, Liu J, Xue C, et al. Affinity Peptide-Based Circularly Permuted Fluorescent Protein Biosensors for Non-Small Cell Lung Cancer Diagnosis. Sensors. 2024. doi:10.3390/s24247899
BibTeX
@article{Xu2024,
author = {Xu, Dengyue and Jiang, Qingyun and Li, Zhi and Shang, Angyang and Liu, Jiaqi and Xue, Chengyu and Shao, Shuai and Zhang, Hangyu and Yuan, Hong and Wu, Bin and Liu, Bo},
title = {Affinity Peptide-Based Circularly Permuted Fluorescent Protein Biosensors for Non-Small Cell Lung Cancer Diagnosis},
journal = {Sensors},
year = {2024},
doi = {10.3390/s24247899}
}
EUVIMED